Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release 1

The recognition of peptidoglycan by cells of the innate immune system has been controversial; both TLR2 and nucleotide-binding oligomerization domain-2 (NOD2) have been implicated in this process. In the present study we demonstrate that although NOD2 is required for recognition of peptidoglycan, this leads to strong synergistic effects on TLR2-mediated production of both pro- and anti-inflammatory cytokines. Defective IL-10 production in patients with Crohn’s disease bearing loss of function mutations of NOD2 may lead to overwhelming inflammation due to a subsequent Th1 bias. In addition to the potentiation of TLR2 effects, NOD2 is a modulator of signals transmitted through TLR4 and TLR3, but not through TLR5, TLR9, or TLR7. Thus, interaction between NOD2 and specific TLR pathways may represent an important modulatory mechanism of innate immune responses.

[1]  M Schwab,et al.  NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression , 2004, Gut.

[2]  Tomohiro Watanabe,et al.  NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.

[3]  J. Glas,et al.  Crohn's disease is associated with a toll-like receptor-9 polymorphism. , 2004, Gastroenterology.

[4]  D. Philpott,et al.  Mini‐review: The role of peptidoglycan recognition in innate immunity , 2004, European journal of immunology.

[5]  B. Franke,et al.  NOD2 mediates anti‐inflammatory signals induced by TLR2 ligands: implications for Crohn's disease , 2004, European journal of immunology.

[6]  D. Binion,et al.  Human Intestinal Microvascular Endothelial Cells Express Toll-Like Receptor 5: A Binding Partner for Bacterial Flagellin , 2004, The Journal of Immunology.

[7]  T. Hartung,et al.  Structural Requirements of Synthetic Muropeptides to Synergize with Lipopolysaccharide in Cytokine Induction* , 2004, Journal of Biological Chemistry.

[8]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[9]  P. Murray,et al.  Role of Nod2 in the Response of Macrophages to Toll-Like Receptor Agonists , 2003, Molecular and Cellular Biology.

[10]  S. Akira,et al.  Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. , 2003, The Journal of clinical investigation.

[11]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[12]  S. Foster,et al.  Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 , 2003, The Journal of Biological Chemistry.

[13]  Yasunori Ogura,et al.  Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation* , 2002, The Journal of Biological Chemistry.

[14]  T. F. Murray,et al.  The Origin of the Synergistic Effect of Muramyl Dipeptide with Endotoxin and Peptidoglycan* , 2002, The Journal of Biological Chemistry.

[15]  J. Schölmerich,et al.  CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium‐treated mice , 2002, European journal of immunology.

[16]  M. Vatn,et al.  Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study , 2002, The Lancet.

[17]  C. Janeway,et al.  RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems , 2002, Nature.

[18]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[19]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[20]  S. Akira,et al.  Synergistic Effect of Muramyldipeptide with Lipopolysaccharide or Lipoteichoic Acid To Induce Inflammatory Cytokines in Human Monocytic Cells in Culture , 2001, Infection and Immunity.

[21]  Y. Ogura,et al.  Human Nod1 Confers Responsiveness to Bacterial Lipopolysaccharides* , 2001, The Journal of Biological Chemistry.

[22]  S. Akira,et al.  Cutting Edge: TLR2-Deficient and MyD88-Deficient Mice Are Highly Susceptible to Staphylococcus aureus Infection1 , 2000, The Journal of Immunology.

[23]  B. Monks,et al.  Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. , 2000, The Journal of clinical investigation.

[24]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[25]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[26]  M. Netea,et al.  Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. , 1996, The Journal of clinical investigation.

[27]  Jean Weissenbach,et al.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.

[28]  S. Van Uum,et al.  Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. , 1995, Journal of applied physiology.

[29]  B. Kullberg,et al.  Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. , 1993, The Journal of infectious diseases.

[30]  J. Meer,et al.  Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. , 1988, Clinical immunology and immunopathology.

[31]  N. Greenberger.  The Evolution of Therapy in Gastroenterology: By Irvin Modlin. 357 pp. Axcan Pharma. Inc., Birmingham, Alabama, 2002. ISBN 2-9807504-0-9 , 2004 .

[32]  S. Targan,et al.  Bacterial flagellin is a dominant antigen in Crohn disease. , 2004, The Journal of clinical investigation.